Hammes, Hans-Peter

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage

Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature

Advanced Glycation End Products researchNitric Oxide and Endothelin Effects

Cited by 4,277

Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy

Hammes, H.-P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., et al. (2003) · Nature Medicine

Advanced Glycation End Products researchRetinal Diseases and Treatments

Cited by 785

Risk Factors for Retinopathy and DME in Type 2 Diabetes—Results from the German/Austrian DPV Database

Hammes, H.-P., Welp, R., Kempe, H.-P., Wagner, C., Siegel, E., Holl, R. W., & DPV Initiative—German BMBF Competence Network Diabetes Mellitus (2015) · PLOS ONE

Retinal Diseases and TreatmentsChronic Kidney Disease and Diabetes

Cited by 131

Impaired agglutination of IgM resulting from non-enzymatic glycation in diabetes mellitus

Hammes, H.-P., Kiefel, V., Laube, H., & Federlin, K. (1990) · Diabetes Research and Clinical Practice

Advanced Glycation End Products researchGlycosylation and Glycoproteins Research

Cited by 23

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy

Oezer, K., Kolibabka, M., Gassenhuber, J., Dietrich, N., Fleming, T., Schlotterer, A., Morcos, M., Wohlfart, P., & Hammes, H.-P. (2023) · Acta Diabetologica

Retinal Diseases and TreatmentsDiabetes Treatment and Management

Cited by 22